EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors

Mats Någård iD, Mei-Lin Ah-See, James Strauss, Trisha Wise-Draper, Howard P Safran, Laura Nadeau, William J Edenfield, Lionel D Lewis, Lone H Ottesen, Yan Li, Ganesh M Mugundu

Cancer Chemotherapy and Pharmacology · 2023

DOI: 10.1007/s00280-023-04554-3 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2023. Verfasst von Mats Någård und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, AstraZeneca, One MedImmune Way, Gaithersburg, MD, 208…. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP1A2, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Adavosertib may alter exposure to substrates of the cytochrome P450 (CYP) family of enzymes. This study assessed its effect on the pharmacokinetics of a cocktail of probe substrates for CYP3A (midazolam), CYP2C19 (omeprazole), and CYP1A2 (caffeine).

Methods

Period 1: patients with locally advanced or metastatic solid tumors received ‘cocktail’: caffeine 200 mg, omeprazole 20 mg, and midazolam 2 mg (single dose); period 2: after 7- to 14-day washout, patients received adavosertib 225 mg twice daily on days 1–3 (five doses), with cocktail on day 3. After cocktail alone or in combination with adavosertib administration, 24-h pharmacokinetic sampling occurred for probe substrates and their respective metabolites paraxanthine, 5-hydroxyomeprazole (5-HO), and 1′-hydroxymidazolam (1′-HM). Safety was assessed throughout.

Results

Of 33 patients (median age 60.0 years, range 41–83) receiving cocktail, 30 received adavosertib. Adavosertib co-administration increased caffeine, omeprazole, and midazolam exposure by 49%, 80%, and 55% (AUC 0–12 ), respectively; AUC 0–t increased by 61%, 98%, and 55%. Maximum plasma drug concentration (C max ) increased by 4%, 46%, and 39%. Adavosertib co-administration increased 5-HO and 1′-HM exposure by 43% and 54% (AUC 0–12 ) and 49% and 58% (AUC0–t), respectively; paraxanthine exposure was unchanged. Adavosertib co-administration decreased C max for paraxanthine and 5–HO by 19% and 7%; C max increased by 33% for 1′-HM. After receiving adavosertib, 19 (63%) patients had treatment-related adverse events (six [20%] grade ≥ 3).

Conclusion

Adavosertib (225 mg bid) is a weak inhibitor of CYP1A2, CYP2C19, and CYP3A. ClinicalTrials.gov NCT03333824

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP1A2NeoplasmsHumansAdultMiddle AgedAgedAged, 80 and overCytochrome P-450 CYP3AMidazolamCaffeineCytochrome P-450 CYP2C19Drug InteractionsCytochrome P-450 Enzyme SystemOmeprazolePyrazolesPyrimidinones

Stichwörter der Autor:innen

AZD1775AdavosertibCYP1A2CYP2C19CYP3APharmacokinetics

Substanzen

Cytochrome P-450 CYP1A2Cytochrome P-450 CYP3AMidazolamCaffeineCytochrome P-450 CYP2C19Cytochrome P-450 Enzyme SystemOmeprazoleadavosertibPyrazolesPyrimidinones

Autor:innen und Institutionen

  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, AstraZeneca, One MedImmune Way, Gaithersburg, MD, 20878, USA. Mats.Nagard@astrazeneca.com.
  • Late-Stage Development, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Mary Crowley Cancer Research Center, Dallas, TX, USA.
  • University of Cincinnati Cancer Center, Cincinnati, OH, USA.
  • Rhode Island Hospital, Lifespan Cancer Institute, Providence, RI, USA.
  • Beaumont Cancer Center, Royal Oak, MI, USA.

ORCID-Profile: Mats Någård

Förderung

  • NCI NIH HHS
  • AstraZeneca

Zitieren

APA

Någård, M., Ah-See, M. L., Strauss, J., Wise-Draper, T., Safran, H. P., Nadeau, L., Edenfield, W. J., Lewis, L. D., Ottesen, L. H., Li, Y., & Mugundu, G. M. (2023). Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-023-04554-3

Vancouver

Någård M, Ah-See ML, Strauss J, Wise-Draper T, Safran HP, Nadeau L, et al. Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 2023. doi:10.1007/s00280-023-04554-3

BibTeX
@article{Ngrd2023,
  author = {Någård, Mats and Ah-See, Mei-Lin and Strauss, James and Wise-Draper, Trisha and Safran, Howard P and Nadeau, Laura and Edenfield, William J and Lewis, Lionel D and Ottesen, Lone H and Li, Yan and Mugundu, Ganesh M},
  title = {Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2023},
  doi = {10.1007/s00280-023-04554-3}
}
Kostenlos starten →